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Abstract 
Review on CPEB4, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
HGNC (Hugo): CPEB4 
Location: 5q35.2 
Local order: UCSC Genome Browser. 
DNA/RNA 
Description 
CPEB4 gene covers 71.98 kb on human 
chromosome 5 (5q35.2), between 173315331 and 
173387313 (according to hg19-Feb_2009, UCSC). 
Transcription 
The mRNA of CPEB4 contains 10 exons and 9 
introns. Multiple transcript variants encoding 
different isoforms (10 splice variants) have been 
found for this gene. 
Protein 
Description 
CPEB4 is a RNA binding protein that belongs to 
the CPEB-family of proteins. In vertebrates, 4 
members (CPEB1, CPEB2, CPEB3, CPEB4) have 
been identified, CPEBs2-4 are closely related 
whereas CPEB1 is the most distant member of the 
family (Wang et al., 2010). All members have a 
conserved carboxy-terminal region, composed of 
two RNA Recognition motifs (RRM) and two zinc-
finger-like motifs (Hake et al., 1998), and a 
regulatory highly variable N-terminal domain. 
10 different isoforms have been described for 
CPEB4: 
- Isoform a: 729 amino acids, 80.2 kDa protein, 
RRM motifs: aa 472-563 and aa 580-662. 
 
 
Diagram of the genomic organization of CPEB4. 
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Diagram of CPEB4 protein in scale (Isoform a). CPEB4 presents 2 different RNA Recognition Motifs (RRM1 - green and 
RRM2 - blue), which recognize U-rich sequences. Moreover, CPEB4 has two Zinc-finger-like motifs (ZnFs - brown). CPEBs 
share these conserved RNA-binding domain at the C-terminal of the protein. 
 
 
- Isoform b: Exon 3 skipped, 712 amino acids, 78.3 
kDa protein. 
- Isoform c: Exon 3 and 4 skipped, 704 amino 
acids, 77.3 kDa protein. 
- Isoform d: Exons 3, 4 and 9 skipped, 639 amino 
acids, 69.8 kDa protein. 
- Isoform e: Exons 3, 4, 5, 6, 7, 8, 9 and 10 skipped, 
389 amino acids, 43.1 KDa protein. 
- Isoform f: Exons 1 and 4 skipped, 339 amino 
acids, 38 kDa protein. 
- Isoform g: Exons 1, 3 and 4 skipped, 322 amino 
acids, 36.2 kDa protein. 
- Isoform h: Exons 1, 2, 3 and 4 skipped, 295 amino 
acids, 33 KDa protein. 
- Isoform i: Exons 1 (partly) 3, 4, 5, 6, 7, 8, 9 and 
10 skipped, 226 amino acids, 25.3 KDa protein. 
- Isoform j: Exons 1 (partly) 4, 6, 7, 8, 9 and 10 
skipped, 146 amino acids, 16.3 kDa protein. 
Expression 
CPEBs are widely expressed in different 
mammalian tissues and tumours and sometimes 
with overlapping patterns. CPEB4 mRNA is highly 
expressed in embryonic stages (E14.5) brain, heart, 
kidney and lung.  
Moreover, a lower expression is also present in 
liver, spleen and ovary (Fernandez-Miranda et al., 
2012). At protein level, an upregulation in 
Pancreatic Ductal Adenocarcinoma (PDA) and 
glioblastoma (Ortiz-Zapater et al., 2011) has also 
been described. At RNA level, CPEB4 
misregulation is present in several types of cancer: 
prostate, breast, skin, lung, brain and digestive 
apparatus (D'Ambrogio et al., 2013) but this 
misregulation requires further characterization 
because CPEB4 mRNA is under a strong post-
transcriptional regulation. 
Localisation 
Cytoplasmic Polyadenylation Element Binding 
protein 4 (CPEB4) is mostly cytosolic, however it 
has been reported that it can be a nucleus-cytoplasm 
shuttling protein in neurons, in response to calcium-
mediated signalling. In fact, CPEB4 becomes 
nuclear in response to focal ischemia and when 
cultured neurons are deprived of oxygen and 
glucose (Kan et al., 2010). 
Function 
CPEBs are RNA binding proteins that recognize 
cis-acting elements named Cytoplasmic 
Polyadenylation Element (CPE), that are located in 
the 3'UTR of some mRNAs. They were originally 
described in Xenopus laevis oocytes, where they 
control translation of maternal mRNAs during 
meiosis by regulation of the length of the polyA tail 
(Hake and Richter, 1994). However, these proteins 
can be also found in other non-germ cells 
suggesting other functions for CPEBs (Costa-
Mattioli et al., 2009; Mendez and Richter, 2001; 
Richter, 2007). CPEB4 recognizes the same CPE as 
CPEB1, although with less affinity (Novoa et al., 
2010; Igea et al., 2010). In oocytes, CPEB4 is 
required for meiotic progression between MI and 
MII and regulates CSF arrest (Igea et al., 2010). In 
somatic cells, CPEB4, together with CPEB, 
regulates mitotic poly(A) tail elongation and is 
required for cell proliferation (Novoa et al., 2010). 
Moreover, CPEB4 also plays a role in cancer where 
overexpression of CPEB4 correlates with increased 
malignancy, tumour growth and vascularization in 
pancreatic cancer and glioblastoma (Ortiz-Zapater 
et al., 2011), suggesting that overexpression of 
CPEB4 can be a general mechanism in cancer 
development and that CPEB4 could behave as an 
oncogene. 
Homology 
CPEB4 orthologs are also present in other species, 
such as Mus musculus (Cpeb4), Xenopus laevis 
(cpeb4), Danio rerio (cpeb4), Drosophila 
melanogaster (Orb2) and Caenorhabditis elegans 
(cpb1-2). 
Mutations 
Note 
Relevant point mutations have been described for 
other members of the CPEB family, such as the 
point mutation T>C in exon 3 of the CPEB3 mRNA  
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(rs11186856), which has been associated with a 
reduced translation efficiency and impaired 
episodic memory (Vogler et al., 2009). However, 
even though there are some point mutations 
described for CPEB4, up to date none of them have 
been proved to have a functional relevance. 
Implicated in 
Pancreatic cancer 
Note 
CPEB4 is overexpressed in human Pancreatic 
Ductal Adenocarcinoma (PDAC) where it supports 
tumour growth, vascularization and invasion (Ortiz-
Zapater et al., 2011). In addition, knockdown of 
CPEB4 both in vitro and in vivo causes significant 
reduction of the malignancy of pancreatic tumor 
cells, suggesting the use of CPEB4 inhibitors as a 
PDA therapy. 
Disease 
The most common type of human pancreatic cancer 
(95%) is pancreatic ductal adenocarcinoma that is 
the fifth most common cause of cancer-related 
deaths worldwide, second only to colon cancer 
among malignancies of the digestive tract (Siegel et 
al., 2013). Despite notable efforts to develop novel 
therapeutic targets, PDA is still highly resistant to 
therapy, with a median survival of 4-6 months and a 
5-year survival rate lower than 5% (Hidalgo, 2010). 
Prognosis 
CPEB4 expression was specifically upregulated in 
human pancreatic cancer, correlating with tumor 
stages. CPEB4 expression is absent in normal 
pancreas, low in low-grade precursor tumor lesions 
(PanIN - Pancreatic Intraepithelial Neoplasia), 
medium in high-grade PanINs and high in well-
differentiated PDAC. These data suggest that 
CPEB4 expression can be a prognostic factor in 
pancreatic carcinogenesis. 
Oncogenesis 
CPEB4 has been reported as a master gene involved 
in the reprogramming of cancer gene expression. 
The pro-oncogenic functions of CPEB4 originate in 
the translational activation of mRNAs that are 
silenced in normal tissue. RNA 
immunoprecipitation (RIP) analysis, identify more 
than 800 transcripts significantly enriched in a 
number of cancer-related cellular functions such as 
cell signalling molecules (Ras-related, Smad3, PI3 
K, CamKII, G-protein coupled-receptor), 
chromatin-remodelling proteins (i.e. histone 
deacetylases, MYST histone acetyltransferase), 
cyclins, apoptosis-related molecules (CASP8, 
BCL2 binding component 3), stress/inflammation 
factors (interleukin 32, HIG1, interferon receptor 2, 
heat shock 70) and genes associated with cell 
migration/metastasis (MMP-7, tissue plasminogen 
activator, β-catenin, Twist) (Ortiz-Zapater et al., 
2011). 
Glioblastoma 
Note 
CPEB4 is overexpressed in human glioblastoma, 
increasing its capacity to proliferate and invade. 
CPEB4 downregulation in vivo correlates with less 
tumour size, proliferation and vascularization 
(Ortiz-Zapater et al., 2011). 
Disease 
Glioblastoma (formerly GlioBlastoma Multiforme, 
GBM) represents both the most common and most 
malignant primary brain tumour variant.  
Its widely infiltrative growth precludes definitive 
surgical resection, and its invariably aggressive 
biological behaviour leads to dismal clinical 
outcome (Wen et al., 2007).  
GBM could arise from a WHO grade II or III 
astrocytoma (secondary GBM) or emerging in a 
fully malignant state (primary GBM) (Ohgaki et al., 
2005). 
Prognosis 
CPEB4 is absent in human normal astrocytes but 
was very abundant in high-grade glioblastoma, 
suggesting a prognostic value for CPEB4 
expression in this tumor. 
Ischemic stroke 
Note 
Ischemic stroke is a leading cause of death and 
dissability worldwide.  
It is produced from a vascular oclussion, which 
reduces the perfussion of the blood into specific 
areas of the brain. The subsequent restoration of the 
blood flow has been demonstrated to exacerbate the 
damage. 
Prognosis 
CPEB4 has been described to shuttle to the nucleus 
of neurons in response to pathological levels of the 
neurotransmitter glutamate (a hallmark of the 
ischemic stroke) both in vitro and in vivo. 
Moreover, the nuclear accumulation of CPEB4 has 
been associated to an enhanced survival of 
hippocampal neurons under low levels of oxygen 
and glucose, pointing to a neuroprotective role of 
CPEB4 (Kan et al., 2010). 
To be noted 
Note 
Joan Gibert and Héctor Anta contributed equally to 
this work and share first authorship. 
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